|
Lori Sames
Chief Executive Officer
Hannah's Hope Foundation
|
|
For the last eight years, Ms. Sames has been managing a virtual biotech, coordinating a collaborative team of scientists to focus on developing treatments for giant axonal neuropathy (GAN). Lori and her husband created Hannah’s Hope Fund (HHF), a 501(c)(3) public charity, in 2008 after their four-year-old daughter received this horrific diagnosis. GAN is the most severe form of inherited neuropathy and in most cases is fatal by age 20.
HHF has raised more than $7 million to fund a natural history study and all preclinical work for the CNS AAV IND, as well as other GAN programs. Thankfully, the AAV intrathecal trial is underway, and seven subjects have been injected. Lori is also focused on an AAV optic program for GAN, and oversees the GAN drug discovery program. Prior to having three lovely daughters, she was a senior project lead for computer software installations at integrated healthcare delivery networks nationwide.
|
|
Helen Haggerty
Distinguished Research Fellow, Immuno and Molecular Toxicology, Drug Safety Evaluation
Bristol-Myers Squibb Company
|
|
Prior to joining Bristol-Myers Squibb in 1993, Dr. Helen Haggerty conducted her postdoctoral fellowship at the University of Pennsylvania in the laboratory of Dr. John Monroe studying B cell signaling. Dr. Haggerty is a distinguished research fellow and department head of Immunotoxicology within Drug Safety Evaluation (DSE). The Immunotoxicology Department has a multifaceted knowledgebase and strong technical expertise in protein therapeutic and small molecule drug development, with experience in program representation, study directing, and immunotoxicity and immunogenicity assay development and evaluation. As the DSE therapeutic area head for Immunology, Dr. Haggerty provides scientific leadership, oversight, and direction for all programs within the immunoscience therapeutic area and serves as an advisor for biopharmaceuticals across the therapeutic areas. She was also responsible for the nonclinical safety evaluation of Orencia and Nulojix. Since joining BMS in 1993, she has had significant experience in critical regulatory meetings, including the preparation and conduct of two successful US FDA Advisory Committee Meetings. She was the PhRMA Deputy Topic Leader for the Expert Working Group that drafted the addendum to ICH S6 guidance on the nonclincial safety evaluation of biologics. Dr. Haggerty is a member of the BIOSafe Leadership Committee, ILSI/HESI Immunotoxicology Technical Committee, American Association of Immunologists, and the Society of Toxicology. She has numerous publications in the fields of immunotoxicology and drug development.
|